Browsing by Author "Schalken, J.A."

Now showing items 1-50 of 332

Anti-sense oligonucleotides in prostate cancer
Schalken, J.A. ; Luna Velez, M.V.
2020, Patent
Pyruvate-lactate exchange and glucose uptake in human prostate cancer cell models. A study in xenografts and suspensions by hyperpolarized [1-(13) C]pyruvate MRS and [(18) F]FDG-PET
Heijster, F.H.A. van; Heskamp, S. ; Breukels, V.; Veltien, A.A. ; Franssen, G.M. ; Jansen, K.F.J. ; Boerman, O.C. ; Schalken, J.A. ; Scheenen, T.W.J. ; Heerschap, A.
2020, Article / Letter to editor (NMR in Biomedicine, vol. 33, iss. 10, (2020), article e4362)
Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review
Uijen, M.J.M.; Lassche, G. ; Grunsven, A.C.H. van ; Tada, Y.; Verhaegh, G.W.C.T. ; Schalken, J.A. ; Driessen, C.M.L.; Herpen, C.M.L. van
2020, Article / Letter to editor (Cancer Treatment Reviews, vol. 89, (2020), article 102069)
Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients
Boxtel, W. van ; Verhaegh, G.W.C.T. ; Engen-van Grunsven, I.A. van ; Strijp, D; Kroeze, L.; Ligtenberg, M.J.L. ; Zon, H. van; Hendriksen, Y.; Keizer, D.; Stolpe, A. van de; Schalken, J.A. ; Herpen, C.M.L. van et al. sine al.
2020, Article / Letter to editor (International Journal of Cancer, vol. 146, iss. 11, (2020), pp. 3196-3206)
Clinical utility of emerging biomarkers in prostate cancer liquid biopsies
Boerrigter, E. ; Groen, L.N. ; Erp, N.P. van ; Verhaegh, G.W.C.T. ; Schalken, J.A.
2020, Article / Letter to editor (Expert Review of Molecular Diagnostics, vol. 20, iss. 2, (2020), pp. 219-230)
Prognostic value of PSMA, c-MET and E-cadherin in salivary duct carcinoma
Boxtel, W. van ; Uijen, M.J.M.; Verhaegh, G.W. ; Willems, Stefan M.; Jonker, M.A. ; Schalken, J.A. ; Engen-van Grunsven, I.C.H. van ; Herpen, C.M.L. van
2020, Article / Letter to editor (Oral Oncology, vol. 110, (2020), article 105018)
(68)Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study
Boxtel, W. van ; Lütje, S.; Engen-van Grunsven, I.C.H. van ; Verhaegh, G.W. ; Schalken, J.A. ; Jonker, M.A. ; Nagarajah, J.; Gotthardt, M. ; Herpen, C.M.L. van
2020, Article / Letter to editor (Theranostics, vol. 10, iss. 5, (2020), pp. 2273-2283)
Validation of a 2-gene mRNA urine test for the detection of >= GG2 prostate cancer in an opportunistic screening population
Rubio-Briones, Jose; Borque-Fernando, Angel; Esteban, Luis M.; Mascaros, Juan M.; Ramirez-Backhaus, Miguel; Casanova, Juan; Schalken, J.A. ; Criekinge, W. van; Dominguez-Escrig, Jose
2020, Article / Letter to editor (Prostate, vol. 80, iss. 6, (2020), pp. 500-507)
Commercialized Blood-, Urinary- and Tissue-Based Biomarker Tests for Prostate Cancer Diagnosis and Prognosis
Visser, W.C.H.; Jong, H. de; Melchers, W.J.G. ; Mulders, P.F.A. ; Schalken, J.A.
2020, Article / Letter to editor (Cancers, vol. 12, iss. 12, (2020), article 3790)
Prior PSMA PET-CT Imaging and Hounsfield Unit Impact on Tumor Yield and Success of Molecular Analyses from Bone Biopsies in Metastatic Prostate Cancer
Smits, M. ; Ekici, K.; Pamidimarri Naga, S. ; Oort, I.M. van ; Sedelaar, M. ; Schalken, J.A. ; Nagarajah, J.; Scheenen, T.W.J. ; Gerritsen, W.R. ; Futterer, J.J. ; Mehra, N. et al. sine al.
2020, Article / Letter to editor (Cancers, vol. 12, iss. 12, (2020), article 3756)
Polyisocyanide Hydrogels as a Tunable Platform for Mammary Gland Organoid Formation
Zhang, Y.; Tang, C. ; Span, P.N. ; Rowan, A.E. ; Aalders, T. ; Schalken, J.A. ; Adema, G.J. ; Kouwer, P.H.J. ; Zegers, M.M.P. ; Ansems, M.
2020, Article / Letter to editor (Advanced Science, vol. 7, iss. 18, (2020), article 2001797)
Introducing PIONEER: a project to harness big data in prostate cancer research
Omar, M.I.; Roobol, M.J.; Ribal, M.J.; Abbott, T.D.; Agapow, P.M.; Araujo, S.; Huisman, H.J. ; Schalken, J.A. ; Wolfinger, R.; Kermani, N.Z.
2020, Article / Letter to editor (Nature Reviews. Urology, vol. 17, iss. 6, (2020), pp. 351-361)
Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study
Benoist, G.E. ; Oort, I.M. van ; Boerrigter, E. ; Verhaegh, G.W. ; Hooij, O. van ; Groen, L.N. ; Mehra, N. ; Gerritsen, W.R. ; Erp, N.P. van ; Schalken, J.A.
2020, Article / Letter to editor (Clinical Chemistry, vol. 66, iss. 6, (2020), pp. 842-851)
Improving the barrier function of damaged cultured urothelium using chondroitin sulfate
Rozenberg, B.B.; Janssen, D.A.W. ; Jansen, C.F.J. ; Schalken, J.A. ; Heesakkers, J.P.F.A.
2020, Article / Letter to editor (Neurourology and Urodynamics, vol. 39, iss. 2, (2020), pp. 558-564)
Urinary Molecular Biomarker Test Impacts Prostate Biopsy Decision Making in Clinical Practice
Shore, N.D.; Hafron, Jason; Langford, Timothy; Stein, Marshall; DeHart, Jessica; Brawer, Michael; Schalken, J.A. ; Groskopf, Jack; Wojno, Kirk
2019, Article / Letter to editor (Urology Practice, vol. 6, iss. 4, (2019), pp. 256-260)
A four-group urine risk classifier for predicting outcomes in patients with prostate cancer
Connell, Shea P.; Yazbek-Hanna, Marcelino; McCarthy, Frank; Hurst, R.; Webb, Martyn; Curley, Helen; Schalken, J.A. ; Whitaker, Hayley
2019, Article / Letter to editor (BJU International, vol. 124, iss. 4, (2019), pp. 609-620)
Clinically significant Prostate Cancer diagnosed using a urinary molecular biomarker-based risk score: two case reports
Minnee, Pieter; Hessels, Daphne; Schalken, J.A. ; Criekinge, W. van
2019, Article / Letter to editor (BMC Urology, vol. 19, iss. 1, (2019), article 124)
Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study
Govers, T.M. ; Hessels, D. ; Vlaeminck-Guillem, Virginie; Schmitz-Draeger, Bernd J.; Stief, Christian G.; Martinez-Ballesteros, Claudio; Sedelaar, J.P.M. ; Criekinge, W. van; Schalken, J.A.
2019, Article / Letter to editor (Prostate Cancer and Prostatic Diseases, vol. 22, iss. 1, (2019), pp. 101-109)
Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma
Boxtel, W. van ; Locati, L.D.; Engen-van Grunsven, A.C.H. van ; Bergamini, C.; Jonker, M.A. ; Fiets, E.; Verhaegh, G.W. ; Schalken, J.A. ; Licitra, L.; Herpen, C.M.L. van
2019, Article / Letter to editor (European Journal of Cancer, vol. 110, (2019), pp. 62-70)
Multicenter Optimization and Validation of a 2-Gene mRNA Urine Test for Detection of Clinically Significant Prostate Cancer before Initial Prostate Biopsy
Haese, Alexander; Trooskens, G.; Steyaert, Sandra; Hessels, Daphne; Brawer, Michael; Vlaeminck-Guillem, Virginie; Schalken, J.A. ; Groskopf, Jack; Criekinge, W. van
2019, Article / Letter to editor (Journal of Urology, vol. 202, iss. 2, (2019), pp. 256-263)
The importance of targeting intracrinology in prostate cancer management
Hamid, A.; Tendi, W.; Sesari, S.S.; Mochtar, C.A.; Umbas, R.; Verhaegh, G.W. ; Schalken, J.A.
2019, Article / Letter to editor (World Journal of Urology, vol. 37, iss. 5, (2019), pp. 751-757)
Suppression of prostate tumor cell survival by antisense oligonucleotide-mediated inhibition of AR-V7 mRNA synthesis
Velez, Maria V.Luna; Verhaegh, G.W. ; Smit, F.P. ; Sedelaar, J.P.M. ; Schalken, J.A.
2019, Article / Letter to editor (Oncogene, vol. 38, iss. 19, (2019), pp. 3696-3709)
A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer
Zhao, F.; Olkhov-Mitsel, E.; Kamdar, S.; Jeyapala, R.; Garcia, J.; Hurst, R.; Hanna, M.Y.; Mills, R.; Tuzova, A.V.; O'Reilly, E.; Kelly, S.; Cooper, C.; Brewer, D.; Perry, A.S.; Clark, J.; Schalken, J.A. ; Fleshner, N.; Bapat, B. et al. sine al.
2018, Article / Letter to editor (Clinical Epigenetics, vol. 10, iss. 1, (2018), pp. 147)
Consensus on molecular imaging and theranostics in prostate cancer
Fanti, S.; Minozzi, S.; Antoch, G.; Banks, I.; Briganti, A.; Carrio, I.; Chiti, A.; Clarke, N.; Eiber, M.; Bono, J. de; Fizazi, K.; Gillessen, S.; Gledhill, S.; Haberkorn, U.; Herrmann, K.; Hicks, R.J.; Lecouvet, F.; Montironi, R.; Ost, P.; O'Sullivan, J.M.; Padhani, A.R.; Schalken, J.A. ; Scher, H.I.; Tombal, B.; Moorselaar, R.J. van; Poppel, H. Van; Vargas, H.A.; Walz, J.; Weber, W.A.; Wester, H.J.; Oyen, W.J.G. et al. sine al.
2018, Article / Letter to editor (Lancet Oncology, vol. 19, iss. 12, (2018), pp. e696-e708)
Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients
Hendriks, R.J.; Dijkstra, S. ; Smit, F.P. ; Vandersmissen, Johan; Voorde, Hendrik Van de; Mulders, P.F.A. ; Oort, I.M. van ; Criekinge, W. van; Schalken, J.A.
2018, Article / Letter to editor (Prostate, vol. 78, iss. 5, (2018), pp. 336-342)
Development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical Management of Patients With Metastatic Castration-Resistant Prostate Cancer
Benoist, G.E. ; Meulen, E. van der ; Oort, I.M. van ; Beumer, J.H.; Somford, D.M.; Schalken, J.A. ; Burger, D.M. ; Erp, N.P. van
2018, Article / Letter to editor (Therapeutic Drug Monitoring, vol. 40, iss. 2, (2018), pp. 222-229)
Urine cell-based DNA methylation classifier for monitoring bladder cancer
Heijden, A.G. van der; Mengual, L.; Ingelmo-Torres, M.; Lozano, J.J.; Rijt-van de Westerlo, Cindy C.M. van; Baixauli, Montserrat; Schalken, J.A. ; Kiemeney, L.A.L.M. ; Witjes, J.A. ; Alcaraz, A.
2018, Article / Letter to editor (Clinical Epigenetics, vol. 10, (2018), article 71)
Genomic Markers in Prostate Cancer Decision Making
Cucchiara, V.; Cooperberg, M.R.; Dall'Era, M.; Lin, D.W.; Montorsi, F.; Schalken, J.A. ; Evans, C.P.
2018, Article / Letter to editor (European Urology, vol. 73, iss. 4, (2018), pp. 572-582)
Analytical challenges in quantifying abiraterone with LC-MS/MS in human plasma
Benoist, G.E. ; Meulen, E. van der ; Lubberman, F.J.E. ; Gerritsen, W.R. ; Smilde, T.J. ; Schalken, J.A. ; Beumer, J.H.; Burger, D.M. ; Erp, N. van
2017, Article / Letter to editor (Biomedical Chromatography, vol. 31, iss. 11, (2017), article e3986)
Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients
Alshalalfa, M.; Verhaegh, G.W.C.T. ; Gibb, E.A.; Santiago-Jimenez, M.; Erho, N.; Jordan, J.; Yousefi, K.; Lam, L.L.C.; Kolisnik, T.; Chelissery, J.; Seiler, R.; Ross, A.E.; Karnes, R.J.; Schaeffer, E.M.; Lotan, T.T.; Den, R.B.; Freedland, S.J.; Davicioni, E.; Klein, E.A.; Schalken, J.A. et al. sine al.
2017, Article / Letter to editor (Oncotarget, vol. 8, iss. 31, (2017), pp. 50804-50813)
A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection
Hendriks, R.J.; Leest, M.M.G. van der; Dijkstra, S. ; Barentsz, J.O. ; Criekinge, W. van; Kaa, C.A. van de ; Schalken, J.A. ; Mulders, P.F.A. ; Oort, I.M. van
2017, Article / Letter to editor (Prostate, vol. 77, iss. 14, (2017), pp. 1401-1407)
Molecular biomarkers to guide precision medicine in localized prostate cancer
Smits, M. ; Mehra, N. ; Sedelaar, M. ; Gerritsen, W.R. ; Schalken, J.A.
2017, Article / Letter to editor (Expert Review of Molecular Diagnostics, vol. 17, iss. 8, (2017), pp. 791-804)
Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model
Dijkstra, S. ; Govers, T.M. ; Hendriks, R.J.; Schalken, J.A. ; Criekinge, W. van; Neste, L. Van; Grutters, J.P.C. ; Sedelaar, J.P.M. ; Oort, I.M. van
2017, Article / Letter to editor (BJU International, vol. 120, iss. 5, (2017), pp. 659-665)
A short-term intervention with selenium affects expression of genes implicated in the epithelial-to-mesenchymal transition in the prostate
Kok, D.E.; Kiemeney, L.A.L.M. ; Verhaegh, G.W.C.T. ; Schalken, J.A. ; Lin, E.N. van; Sedelaar, J.P.M. ; Witjes, J.A. ; Hulsbergen-van de Kaa, C.A. ; Veer, P. van 't; Kampman, E. ; Afman, L.A. et al. sine al.
2017, Article / Letter to editor (Oncotarget, vol. 8, iss. 6, (2017), pp. 10565-10579)
Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions
Hendriks, R.J.; Oort, I.M. van ; Schalken, J.A.
2017, Article / Letter to editor (Prostate Cancer and Prostatic Diseases, vol. 20, iss. 1, (2017), pp. 12-19)
Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy
Taille, A. de la; Martinez-Pineiro, L.; Cabri, P.; Houchard, A.; Schalken, J.A.
2017, Article / Letter to editor (BJU International, vol. 119, iss. 1, (2017), pp. 74-81)
Urothelium update: how the bladder mucosa measures bladder filling
Janssen, D.A.W. ; Schalken, J.A. ; Heesakkers, J.P.F.A.
2017, Article / Letter to editor (Acta Physiologica, vol. 220, iss. 2, (2017), pp. 201-217)
miRNA-520f Reverses Epithelial-to-Mesenchymal Transition by Targeting ADAM9 and TGFBR2
Kampen, J.G.M. van; Hooij, O. van ; Jansen, C.F.J. ; Smit, F.P. ; Noort, P.I.; Schultz, I.; Schaapveld, R.Q.J.; Schalken, J.A. ; Verhaegh, G.W.C.T.
2017, Article / Letter to editor (Cancer Research, vol. 77, iss. 8, (2017), pp. 2008-2017)
Label retention and stem cell marker expression in the developing and adult prostate identifies basal and luminal epithelial stem cell subpopulations
Ceder, J.A.; Aalders, T. ; Schalken, J.A.
2017, Article / Letter to editor (Stem Cell Research & Therapy, vol. 8, iss. 1, (2017), article 95)
TRPV4 channels in the human urogenital tract play a role in cell junction formation and epithelial barrier.
Janssen, D.A.W. ; Jansen, CJ; Hafmans, T.G. ; Verhaegh, G.W. ; Hoenderop, J.G. ; Heesakkers, J.P. ; Schalken, J.A.
2016, Article / Letter to editor (Acta Physiologica, vol. 218, iss. 1, (2016), pp. 38-48)
Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer
Schalken, J.A. ; Fitzpatrick, J.M.
2016, Article / Letter to editor (BJU International, vol. 117, iss. 2, (2016), pp. 215-225)
XRP44X, an Inhibitor of Ras/Erk Activation of the Transcription Factor Elk3, Inhibits Tumour Growth and Metastasis in Mice
Semenchenko, K.; Wasylyk, C.; Cheung, H.; Tourrette, Y.; Maas, P.; Schalken, J.A. ; Pluijm, G. van der; Wasylyk, B.
2016, Article / Letter to editor (PLoS One, vol. 11, iss. 7, (2016), article e0159531)
TRPV4 mediates afferent pathways in the urinary bladder. A spinal c-fos study showing TRPV1 related adaptations in the TRPV4 knockout mouse.
Janssen, D.A.W. ; Hoenderop, J.G.J. ; Heesakkers, J.P.F.A. ; Schalken, J.A.
2016, Article / Letter to editor (Pflügers Archiv : European Journal of Physiology, vol. 468, iss. 10, (2016), pp. 1741-1749)
A five-gene expression signature to predict progression in T1G3 bladder cancer
Heijden, A.G. van der; Mengual, L.; Lozano, J.J.; Ingelmo-Torres, M.; Ribal, M.J.; Fernandez, P.L.; Oosterwijk, E. ; Schalken, J.A. ; Alcaraz, A.; Witjes, J.A.
2016, Article / Letter to editor (European Journal of Cancer, vol. 64, (2016), pp. 127-136)
Validatie van een nieuwe urinetest voor klinisch significante prostaatkanker.
Hendriks, R.; Dijkstra, S; Cornel, E.; Jannink, S.; Jong, H. de; Hessels, D.; Smit, F.; Melchers, W.J. ; Leyten, G.; Reijke, T. de; Vergunst, H.; Kil, P.; Knipscheer, B.C. ; Hulsbergen-van de Kaa, C.A. ; Mulders, P.F.A. ; Oort, I. van; Schalken, J.A. et al. sine al.
2016, Article / Letter to editor (Tijdschrift voor Urologie, vol. 6, (2016), pp. 34-43)
Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide
Benoist, G.E. ; Hendriks, R.J.; Mulders, P.F.A. ; Gerritsen, W.R. ; Somford, D.M.; Schalken, J.A. ; Oort, I.M. van ; Burger, D.M. ; Erp, N. van
2016, Article / Letter to editor (Clinical Pharmacokinetics, vol. 55, iss. 11, (2016), pp. 1369-1380)
Comparative analysis of prostate cancer specific biomarkers PCA3 and ERG in whole urine, urinary sediments and exosomes
Hendriks, R.J.; Dijkstra, S. ; Jannink, S.A.; Steffens, M.G.; Oort, I.M. van ; Mulders, P.F.A. ; Schalken, J.A.
2016, Article / Letter to editor (Clinical Chemistry and Laboratory Medicine, vol. 54, iss. 3, (2016), pp. 483-492)
Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
Neste, L. Van; Hendriks, R.J.; Dijkstra, S. ; Trooskens, G.; Cornel, E.B.; Jannink, S.A.; Jong, H. de; Hessels, D.; Smit, F.P.; Melchers, W.J.G. ; Leyten, G.; Reijke, T.M. de; Vergunst, H.; Kil, P.; Knipscheer, B.C. ; Kaa, C.A. van de ; Mulders, P.F.A. ; Oort, I.M. van ; Criekinge, W. van; Schalken, J.A. et al. sine al.
2016, Article / Letter to editor (European Urology, vol. 70, iss. 5, (2016), pp. 740-748)
Major milestones in translational oncology
Dragani, T.A.; Castells, A.; Kulasingam, V.; Diamandis, E.P.; Earl, H.; Iams, W.T.; Lovly, C.M.; Sedelaar, J.P.M. ; Schalken, J.A.
2016, Article / Letter to editor (BMC Medicine, vol. 14, iss. 1, (2016), pp. 110)
Involvement of orphan nuclear receptor COUP-TFII in cadherin-6 and cadherin-11 regulation: implications in development and cancer
Bringuier, P.P.; Schalken, J.A. ; Hervieu, V.; Giroldi, L.A.
2015, Article / Letter to editor (Mechanisms of Development, vol. 136, (2015), pp. 64-72)

Now showing items 1-50 of 332

Search Repository

Browse

All of Repository

Radboud Repository

Browsing by Author "Schalken, J.A."

Search Repository

Browse

All of Repository